T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

T3 liothyronine is a synthetic version of the thyroid hormone, triiodothyronine (T3). T3, produced by the thyroid gland, regulates various processes in the body, including energy production, temperature regulation and metabolism of carbohydrates and proteins. T3 liothyronine is used in the treatment of hypothyroidism, a condition in which the body doesn’t produce enough thyroid hormones.

T3 liothyronine was first approved by the FDA in 1956. Liothyronine is more potent as compared to levothyroxine (T4) and has a similar pharmacokinetic profile and bioavailability. T3 is a well-researched drug and research shows that it might benefit people with depression, infertility and multiple sclerosis. At Element Sarms, liquid T3 for sale is restricted to educational and research purposes.

From Pubchem

IUPAC Name:(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
Synonyms: 3,3',5-Triiodo-L-thyronine, 6893-02-3, Tresitope
Molecular Formula: C15H12I3NO4
Molecular Weight: 650.97 g/mol
CAS Number: 15785-49-6
PubChem CID: 5920

1. T3 Liothyronine and Hypothyroidism

Liothyronine has been approved by the FDA as a replacement and supplementation therapy in patients with hypothyroidism. American Thyroid Association recommends levothyroxine (T4) as a standard therapy for hypothyroidism. However, some patients still continue to experience impaired quality of life. One study found that 88.47% of patients on combination therapy using T3 and T4 achieved therapeutic TSH levels. Further, it improved their quality of life without significant adverse effects [1].

Similarly, one study was conducted to check the efficacy of liothyronine monotherapy in female hypothyroid patients with residual symptoms on T4 monotherapy and T3/T4 combination therapy. Participants received T3 and T4 in a non-blinded randomized cross-over fashion. The results found that T3 monotherapy improved the quality of life in patients with residual symptoms and short-term therapy didn’t induce clinical hypothyroidism [2].

2. T3 Liothyronine and Weight Loss

Triiodothyronine increases the body’s metabolic rate, leading to greater energy expenditure. As a result, T3 liothyronine causes weight loss. In a randomized double-blinded cross-over study, T3 and T4 were administered to subclinical hypothyroidism patients aged 70 years or above. The results found that participants who took T4 lost 1.1 kg weight and those who were on T3 experienced weight loss of 2.5 kg. Furthermore, fat mass decreased by an average of 0.7kg and 1.5kg in the T4 and T3 group respectively [3].

Furthermore, one more study was conducted to evaluate the effectiveness of thyroid hormone replacement with levothyroxine or liothyronine. 14 subjects were recruited in the study and they took either T3 or T4 three times a day for 6 weeks. The results found that T3 resulted in greater weight loss and thyroid hormone action on lipid metabolism [4].

3. T3 Liothyronine and Depression

Research shows that T3 acts in the nucleus of a cell and influences gene expression and metabolism in every organ of the body. It might also enhance neurogenesis in the central nervous system. Furthermore, there is a possibility that T3 directly act as a neurotransmitter and research shows its action at noradrenergic, serotonergic and beta-adrenergic neurons [5].

Studies indicate that adding T3 Liothyronine can be used as an augmentation strategy for unipolar depression in combination with other drugs, particularly selective serotonin reuptake inhibitors and primarily tricyclic antidepressants. However, long-term studies are needed to confirm its efficacy and safety [6].

4. T3 liothyronine and Multiple Sclerosis

Thyroid hormones have been known to promote remyelination in multiple sclerosis in animal models. Research shows that T3 promotes the differentiation of oligodendrocyte precursor cells into mature oligodendrocytes. In phase one randomized controlled trials, six clinically stable patients with MS were randomized to receive a placebo or liothyronine. The results found that short-term use of liothyronine is safe and well-tolerated with a maximum tolerated dose of 75 mcg total daily dose [7].

Furthermore, the phase Ib clinical trial replicated these results and found T3 to be well-tolerated in MS. Researchers observed proteomic changes in CSF that suggest the biological action of T3 within the central nervous system [8].

5. Summary

T3 liothyronine is a synthetic version of the thyroid hormone that regulates various functions in the body, including metabolism and temperature regulation. T3 liothyronine has been approved by the FDA for the treatment of hypothyroidism. Research shows that it induces weight loss and can be used as an augmentation therapy and myelinating agent in MS. If you are keen researchers wondering where to buy liquid T3, purchase liquid T3 from Element Sarms to elevate your research.

1. Tariq, A., et al., Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life. South Med J, 2018. 111(6): p. 363-369.
2. Bjerkreim, B.A., et al., Effect of Liothyronine Treatment on Quality of Life in Female Hypothyroid Patients With Residual Symptoms on Levothyroxine Therapy: A Randomized Crossover Study. Front Endocrinol (Lausanne), 2022. 13: p. 816566.
3. P, M., et al., - Physiologic Effects of Levothyroxine and Liothyronine in the in Older Individuals. J Endocr Soc, 2021. 5(Suppl 1).
4. Celi, F.S., et al., Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab, 2011. 96(11): p. 3466-74.
5. Lisa J. Rosenthal, M.D. ,, Whitney S. Goldner, M.D. , and, and John P. O'Reardon, M.D., T3 Augmentation in Major Depressive Disorder: Safety Considerations. American Journal of Psychiatry, 2011. 168(10): p. 1035-1040.
6. Touma, K.T.B., A.M. Zoucha, and J.R. Scarff, Liothyronine for Depression: A Review and Guidance for Safety Monitoring. Innov Clin Neurosci, 2017. 14(3-4): p. 24-29.
7. Wooliscroft, L., et al., Phase I randomized trial of liothyronine for remyelination in multiple sclerosis: A dose-ranging study with assessment of reliability of visual outcomes. Multiple Sclerosis and Related Disorders, 2020. 41: p. 102015.
8. Newsome, S.D., et al., A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MS. Neurotherapeutics, 2023.